January 17, 2021
Business News

Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020


LA CHAUX DU FONDS, Switzerland–()–Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin for relapsed/refractory T-Cell Lymphoma patients at the upcoming 62nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually from December 5 – 8, 2020.

The poster presentation at ASH, 2020 includes interim data from a multi-center, open label, Phase I/II study in patients with T cell lymphoma (NCT03770000) with the objective of determining the MTD/optimal dose of Tenalisib given in combination with Romidepsin and assessing the preliminary…



Click here to view the original article.

Related Posts

You might also like ...

post featured image
Parler CEO: ‘No indication’ Big Tech shutdown threats were ‘deadly serious’ until last minute – Fox News
post featured image
UK must not do trade deals with rights abusers, foreign minister says
post featured image
Bayer aims to help CureVac with COVID-19 vaccine output, says CEO